Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 30 (4), 285-312

Meptazinol. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy

Review

Meptazinol. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy

B Holmes et al. Drugs.

Abstract

Meptazinol is a new opioid-type analgesic with mixed agonist/antagonist properties. It may be given orally, intravenously or intramuscularly. In studies in patients with moderate to severe pain of various aetiologies, usually following surgery or in obstetrics, the characteristics of analgesia with meptazinol were comparable to those seen with equianalgesic doses of pentazocine, pethidine or a combination of dextropropoxyphene and paracetamol. Preoperative use and use as a component of anaesthesia require further investigation before conclusions may be drawn on its effectiveness in these areas. Onset of action, recorded in a few studies, was faster than that with the other analgesics but duration was shorter than that of morphine, buprenorphine and pentazocine. Only a small number of patients with chronic pain have received long term therapy with meptazinol; in such patients there was no need for increased doses as treatment progressed. Respiratory depression has only been observed in patients receiving meptazinol as a premedication or while undergoing anaesthesia. Similarly any haemodynamic changes have been limited to preoperative patients or patients undergoing anaesthesia. Like other agonist/antagonist analgesic drugs, the abuse potential of meptazinol seems relatively low, but only wider clinical use for longer periods can establish this with certainty. The most commonly reported side effects have been gastrointestinal in nature, and although the incidence of central nervous system side effects has been relatively low, drowsiness and dizziness have caused occasional problems. Thus, meptazinol is a relatively potent but safe addition to the analgesics available for treatment of the patient with moderate to severe pain.

Similar articles

  • Clinical Review of Parenteral Meptazinol
    PJ Robson. Postgrad Med J 59 Suppl 1, 85-92. PMID 6340086. - Review
    The literature on the clinical use of parenteral meptazinol and its clinical pharmacology, is reviewed. Meptazinol is a centrally acting drug which produces analgesia of …
  • Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain States
    PJ Hoskin et al. Drugs 41 (3), 326-44. PMID 1711441. - Review
    The agonist-antagonist opioid analgesics are a heterogeneous group of drugs with moderate to strong analgesic activity comparable to that of the pure agonist opioids such …
  • Characterization of the Opioid Receptor Binding and Animal Pharmacology of Meptazinol
    GW Pasternak et al. Postgrad Med J 61 Suppl 2, 5-12. PMID 3001685.
    Meptazinol is a unique opioid analgesic. Binding studies suggest a relative selectivity for mu 1 sites, as opposed to the other opioid receptor binding sites. This bindin …
  • Meptazinol: A Novel Mu-1 Selective Opioid Analgesic
    K Spiegel et al. J Pharmacol Exp Ther 228 (2), 414-9. PMID 6141283.
    Meptazinol is a unique centrally active opioid analgesic, differing in many respects from the classical opiates or mixed antagonists. Although the overall binding of a se …
  • Oral meptazinol--United Kingdom Experience
    JA Henry. Postgrad Med J 61 Suppl 2, 29-34. PMID 3909133. - Review
    An oral formulation of meptazinol has been developed and marketed in the United Kingdom. The 200 mg tablet has a potency similar to dextropropoxyphene 32.5 mg/paracetamol …
See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

References

    1. Postgrad Med J. 1985;61 Suppl 2:27-8 - PubMed
    1. Curr Med Res Opin. 1984;9(4):246-52 - PubMed
    1. J Int Med Res. 1982;10(2):104-8 - PubMed
    1. J Pharm Pharmacol. 1979 Nov;31(11):793-5 - PubMed
    1. Curr Med Res Opin. 1975;3(4):181-6 - PubMed

LinkOut - more resources

Feedback